Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

6.5K
Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
6.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Non-pharmacological interventions for enhancing the working life of patients with lupus: a systematic review.

Lupus·2018
Same author

Disease-specific quality of life in patients with lupus nephritis.

Lupus·2017
Same author

Breast cancer in systemic lupus erythematosus (SLE): receptor status and treatment.

Lupus·2017
Same author

The prevalence and determinants of anti-DFS70 autoantibodies in an international inception cohort of systemic lupus erythematosus patients.

Lupus·2017
Same author

Preventing the development of SLE: identifying risk factors and proposing pathways for clinical care.

Lupus·2016
Same author

What investigations are needed to optimally monitor for malignancies in SLE?

Lupus·2015

Related Experiment Video

Updated: Mar 14, 2026

Ultrasonographic Evaluation of Breast Cancer-related Lymphedema
05:44

Ultrasonographic Evaluation of Breast Cancer-related Lymphedema

Published on: January 12, 2017

10.7K

Breast cancer in systemic lupus.

S Bernatsky1,2, R Ramsey-Goldman3, M Petri4

  • 11 Faculty of Medicine, McGill University, Montreal, Canada.

Lupus
|October 1, 2016
PubMed
Summary

Systemic lupus erythematosus (SLE) patients show a decreased breast cancer risk compared to the general population. This study found older age, not clinical factors like disease activity or medication, was linked to cancer in SLE patients.

Keywords:
Breast cancersystemic lupus erythematosus

More Related Videos

The bm12 Inducible Model of Systemic Lupus Erythematosus SLE in C57BL/6 Mice
12:04

The bm12 Inducible Model of Systemic Lupus Erythematosus SLE in C57BL/6 Mice

Published on: November 1, 2015

19.0K
Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma
10:21

Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma

Published on: September 20, 2024

941

Related Experiment Videos

Last Updated: Mar 14, 2026

Ultrasonographic Evaluation of Breast Cancer-related Lymphedema
05:44

Ultrasonographic Evaluation of Breast Cancer-related Lymphedema

Published on: January 12, 2017

10.7K
The bm12 Inducible Model of Systemic Lupus Erythematosus SLE in C57BL/6 Mice
12:04

The bm12 Inducible Model of Systemic Lupus Erythematosus SLE in C57BL/6 Mice

Published on: November 1, 2015

19.0K
Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma
10:21

Author Spotlight: Exploring the Role of Inflammation in the Co-occurrence of Primary Sjogren's Syndrome and Lung Adenocarcinoma

Published on: September 20, 2024

941

Area of Science:

  • Rheumatology
  • Oncology
  • Epidemiology

Background:

  • Systemic lupus erythematosus (SLE) is associated with a reduced incidence of breast cancer compared to the general population.
  • Understanding the factors influencing breast cancer risk in SLE patients is crucial for risk stratification and management.

Purpose of the Study:

  • To evaluate demographic and clinical characteristics associated with breast cancer risk in a large cohort of SLE patients.
  • To determine the influence of disease activity, autoantibody positivity, and medication use on breast cancer development in SLE.

Main Methods:

  • A case-cohort study was conducted using a multi-center international SLE patient sample.
  • Breast cancer hazard ratios (HR) were calculated, adjusting for SLE duration and considering time-dependent measures of anti-dsDNA positivity, disease activity, and drug exposures.

Main Results:

  • The study included 86 SLE breast cancer cases and 4498 cancer-free SLE controls, with an average follow-up of 7.6 years.
  • SLE breast cancer cases were more likely to be white and older at cohort entry compared to controls.
  • No significant associations were found between breast cancer development and anti-dsDNA positivity, cumulative disease activity, or most drug exposures over time.

Conclusions:

  • Older age at cohort entry was the primary factor associated with breast cancer in this SLE cohort.
  • There was limited evidence that studied clinical factors, including disease activity and specific drug use, strongly drive breast cancer risk in SLE.
  • Further research is warranted to identify factors contributing to the observed lower breast cancer risk in SLE patients.